Thursday 16 October, 2025
Introduction: Ritonavir is a protease inhibitor (PI) with activity against HIV [1]. Due to its neurological and gastrointestinal side effects,…
Read moreAbstracts
Adaptive trial designs: opportunities and challenges
Thursday 16 October, 2025
The use of adaptive designs can increase the efficiency of drug development by improving our ability to efficiently learn about…
Read moreMechanistic Modeling Projections of Antibody Persistence After Homologous Booster Regimens of COVID-19 Vaccine Ad26.COV2.S in Humans
Thursday 16 October, 2025
Objectives: To project the percentages of SARS-CoV-2–seronegative participants at baseline with quantifiable antibodies at 24 months (antibody persistence) following vaccination…
Read moreQuantifying the Persistence of Immunogenicity After a Single Dose of Ad26.COV2.S in Humans Using a Mechanistic Modeling & Simulation Approach
Thursday 16 October, 2025
Objective: To quantify the persistence of humoral immunity after a single injection of 5×1010 viral particles (vp) of the Janssen Ad26…
Read moreVisualising and integrating automated model development within a validated environment
Thursday 16 October, 2025
Objective: The utilization of tools for automated model development results in a challenge to re-think and update common workflows and…
Read morePopulation pharmacokinetics of a truncated milk fat globule-EGF factor 8 (NP-011) for optimal dose prediction on liver fibrosis
Thursday 16 October, 2025
Objectives: NP-011 is a new human recombinant protein produced by the structural truncation of milk fat globule-EGF factor 8. NP-011…
Read moreOverview of Korean Pharmacometrics Modeling Library and web-based pharmacometrics platform
Thursday 16 October, 2025
Objectives: Since, an increasing number of pharmacometrics (PM) models have been developed based on data in Korea, which leads to…
Read moreModel-based meta-analysis of relationship between pioglitazone and histological outcomes in non-alcoholic steatohepatitis patients
Thursday 16 October, 2025
Objectives: Non-alcoholic fatty liver disease (NAFLD) is a global pandemic health problem with a prevalence of approximately 30% worldwide population[1]….
Read moreDevelopment of a Physiological-Based Pharmacokinetic Model for Ritonavir: Unraveling its Triphasic Effects as CYP3A Inhibitor, CYP3A Inducer, and Pgp Inhibitor.
Thursday 16 October, 2025
Introductions: Ritonavir (RTV) was originally approved for the treatment of human immunodeficiency virus (HIV) infection. Currently, the drug is no…
Read moreDevelopment of a physiological-based pharmacokinetic model for tegoprazan: its application to prediction of drug-drug interactions with clarithromycin
Thursday 16 October, 2025
Introductions: Tegoprazan is a novel potassium-competitive acid blocker (P-CAB) developed by CJ Healthcare (Korea). It exhibits its antisecretory effects by competitively…
Read more